Mayo Alliance Prognostic System (MAPS) Score
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10⁹/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–2
- Intermediate Risk3–4
- High Risk5–6
The Mayo Alliance Prognostic System (MAPS) Score calculates assessing prognosis of systemic mastocytosis using clinical and molecular risk factors. Key inputs include sm type. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.
Clinical Indication
The Mayo Alliance Prognostic System (MAPS) Score is indicated for bedside clinical practice to support Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Regular reassessment recommended as disease status may change over time.
MAPS Score = SM Type points + Age points + Platelet points + ALP points + Adverse mutations points. Maximum score 6 points (Advanced SM: 2 + Age >60: 1 + Platelets <150: 1 + Elevated ALP: 1 + Adverse mutations: 1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| sm_type | string | Yes | Type of systemic mastocytosis according to WHO classification. Indolent SM (ISM) and smoldering SM (SSM) have better prognosis than advanced SM subtypes |
| patient_age | integer | Yes | Patient age in years. Age >60 years is associated with worse prognosis in systemic mastocytosis(years) |
| platelet_count | float | Yes | Platelet count in ×10⁹/L. Thrombocytopenia (<150 ×10⁹/L) is an adverse prognostic factor associated with advanced disease(×10⁹/L) |
| serum_alp | string | Yes | Serum alkaline phosphatase level relative to normal range. Elevated ALP indicates possible liver involvement or bone disease in systemic mastocytosis |
| adverse_mutations | string | Yes | Presence of adverse mutations including ASXL1, RUNX1, and NRAS. These mutations are associated with poor prognosis and advanced disease progression |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Low Risk | Excellent prognosis |
| 3–4 | Intermediate Risk | Intermediate prognosis |
| 5–6 | High Risk | Poor prognosis |
Evidence-Based References (EBM)
- Pardanani A, Reichard KK, Zblewski D, Abdelrahman RA, Wassie EA, Koschmann J, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018 Nov 27;2(21):2964-2975. doi: 10.1182/bloodadvances.2018024768.DOI: 10.1182/bloodadvances.2018024768
- Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436.DOI: 10.1111/all.12436
- Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JN, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019 Nov;6(11):e638-e649. doi: 10.1016/S2352-3026(19)30166-8.DOI: 10.1016/S2352-3026(19)30166-8
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544.DOI: 10.1182/blood-2016-03-643544